BIO-TECHNE DECLARES DIVIDEND

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) has announced a dividend payout of $0.08 per share for the quarter ended September 30, 2023. The dividend will be payable on November 24, 2023, to all common shareholders of record on November 10, 2023. Future cash dividends will be considered on a quarterly basis.

MINNEAPOLIS, Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2023. The quarterly dividend will be payable November 24, 2023, to all common shareholders of record on November 10, 2023. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,200 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­-techne.com.

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact:	David Clair, Vice President, Investor Relations & Corporate Development
	David.Clair@bio-techne.com
	612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-301972191.html

SOURCE Bio-Techne Corporation

FAQ

What is the dividend payout announced by Bio-Techne Corporation?

Bio-Techne Corporation has announced a dividend payout of $0.08 per share for the quarter ended September 30, 2023.

When will the dividend be payable?

The dividend will be payable on November 24, 2023.

Who will be eligible for the dividend?

All common shareholders of record on November 10, 2023, will be eligible for the dividend.

How often will future cash dividends be considered?

Future cash dividends will be considered on a quarterly basis.

What is Bio-Techne Corporation?

Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

What do Bio-Techne products assist in?

Bio-Techne products assist in scientific investigations into biological processes, drug discovery efforts, and accurate clinical tests and diagnoses.

What is the net sales generated by Bio-Techne in fiscal 2023?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023.

How many employees does Bio-Techne have?

Bio-Techne has approximately 3,200 employees worldwide.

Where can I find more information about Bio-Techne and its brands?

For more information on Bio-Techne and its brands, please visit www.bio-techne.com.